Repurposing Clinically Approved Drugs to Modulate DNA Repair Pathways in CRISPR Genome Editing

Study Background and Research Question

DNA double-strand breaks (DSBs) are critical lesions that occur spontaneously or in response to exogenous insults such as ionizing radiation and chemotherapeutic drugs. The ability to precisely control the repair of DSBs underpins many genetic engineering techniques, particularly those involving CRISPR/Cas9 genome editing. In mammalian cells, DSBs are primarily repaired via nonhomologous end joining (NHEJ) or microhomology-mediated end joining (MMEJ), with homology-directed repair (HDR) providing a less frequent but more precise pathway. Each pathway results in distinct genetic outcomes—NHEJ and MMEJ typically introduce small indels, while HDR allows precise sequence changes using a DNA template. This mechanistic diversity is exploited in disease modeling, gene therapy, and synthetic lethality-based cancer treatment. However, the efficiency and fidelity of these pathways can be suboptimal or unpredictable, prompting a key question: Can existing, clinically safe drugs be repurposed to controllably shift DNA repair pathway choice, thereby enhancing the precision and utility of genome editing platforms?

Key Innovation from the Reference Study

The referenced study systematically investigates the effect of over 7,000 FDA-approved drugs on DSB repair pathway distribution in human induced pluripotent stem cells (hiPSCs) using a high-throughput screening strategy (paper). This large-scale repurposing effort represents a significant advance, as it moves beyond isolated case studies and provides a resource for identifying both inhibitors and enhancers of NHEJ, MMEJ, and HDR. Moreover, the study uncovers functional roles for proteins such as estrogen receptor 2 (ESR2) and aldehyde oxidase 1 (AOX1) in modulating repair pathway outcomes—insights that may translate to new combinatorial approaches for synthetic lethality in cancer cells. The prospect of fine-tuning repair pathways with characterized, safe compounds opens new avenues for precision genome engineering and targeted therapy.

Methods and Experimental Design Insights

The research team employed a robust experimental workflow centered on 409B2 hiPSCs expressing doxycycline-inducible Cas9 (iCRISPR). Genome editing was targeted to the FRMD7 locus, with cells exposed to individual drug treatments during editing. Cellular outcomes were assessed using a resazurin-based viability assay and high-throughput Illumina sequencing to quantitatively profile editing outcomes and assign them to specific repair pathways (paper). The scale of the screen (n = 7,240 conditions) enabled the mapping of drug-induced shifts in cell survival, precise edits (HDR), and indel profiles related to NHEJ and MMEJ. This approach allowed identification of drugs that selectively enhance or inhibit distinct repair mechanisms, as well as those that induce synthetic lethality when combined with pathway-specific inhibitors.

Protocol Parameters

• assay | resazurin fluorescence cell viability | 1.0 μg/mL resazurin | applicability: cell survival post-editing | rationale: quantitative assessment of drug-induced cytotoxicity | paper
• genome editing reagent | doxycycline-inducible Cas9 (iCRISPR) | 1 μg/mL doxycycline | applicability: controlled Cas9 activation | rationale: minimizes off-target DSBs | paper
• sequencing readout | Illumina, paired-end | 150 bp reads | applicability: fine mapping of indels and HDR events | rationale: high sensitivity for pathway assignment | paper
• drug treatment window | 24 hours during editing | screening of >7,000 compounds | applicability: acute modulation of repair pathways | rationale: captures immediate drug effects | paper
• workflow suggestion | validated ryanodine receptor antagonist (e.g., dantrolene sodium salt) | 5–10 μM (DMSO stock) | applicability: calcium signaling modulation in parallel assays | rationale: mechanistic dissection of calcium-dependent repair pathway influences | workflow_recommendation

Core Findings and Why They Matter

Several key outcomes emerge from this systematic drug screen. First, distinct classes of clinically approved drugs can bias the choice of DSB repair pathway, with some compounds enhancing HDR and others suppressing NHEJ or MMEJ (paper). Notably, silencing ESR2 in combination with NHEJ inhibition leads to a synergistic, mean 4.6-fold increase in HDR frequency, providing a powerful strategy for precise genome editing. The study also identifies drugs that produce synthetic lethality when paired with repair pathway blockade, suggesting applications in precision oncology. The ability to modulate DNA repair outcomes with established pharmacological agents is transformative for applications ranging from therapeutic gene correction to genome-wide knockout screens, and for expanding the use of CRISPR in disease modeling and immunotherapy.

Comparison with Existing Internal Articles

Several internal resources discuss the mechanistic interplay between calcium signaling, ryanodine receptor antagonists, and DNA repair modulation. For example, Molecular Beacon (2024) highlights how dantrolene sodium salt, a calmodulin-dependent ryanodine receptor antagonist, is leveraged in translational research to dissect calcium-dependent influences on genome editing and synthetic lethality workflows. Further, Calpain Inhibitor II expands on the use of dantrolene for precise modulation of intracellular calcium release, supporting advanced CRISPR pathway studies and neurodegenerative disease models. These articles underscore the value of integrating ryanodine receptor antagonists in research aiming to modulate repair pathway choice, complementing the current paper's findings that pharmacological pathway shifts can be achieved with high specificity and reproducibility. Additionally, other internal reviews affirm the utility of high-purity compounds, such as those from APExBIO, for workflows requiring consistent calcium signaling modulation and DNA repair analysis.

Limitations and Transferability

Despite its breadth, the study is constrained by several factors. The primary cell system—human iPSCs—may not recapitulate all features of somatic or cancer cells, and the acute drug treatment window does not account for chronic effects or in vivo pharmacokinetics. Additionally, while the screen identifies many promising drug-pathway interactions, mechanistic validation for each candidate is limited. Transferability to disease models or clinical settings requires careful optimization of dosing, timing, and combinatorial regimens. Moreover, the study does not directly explore the role of calcium signaling or ryanodine receptor antagonists in pathway modulation, though internal literature and workflow recommendations suggest this as a promising area for further investigation (internal article).

Research Support Resources

To facilitate research on DNA repair pathway choice and calcium signaling modulation, researchers may employ validated compounds such as Dantrolene, sodium salt (SKU B6329), a potent, calmodulin-dependent ryanodine receptor antagonist with high purity and extensive quality control data (source: product_spec). Dantrolene sodium salt is particularly suited for studies involving intracellular calcium release inhibition, synthetic lethality models, and CRISPR genome editing workflows where precise modulation of the ryanodine receptor signaling pathway is desired. APExBIO supplies this compound with comprehensive documentation to support reproducible and robust experimental design. For further mechanistic insights and protocol adaptation, internal literature resources detailed above provide practical guidance.